Status:
UNKNOWN
Management of Albuminuria in Hypertensive Diabetics
Lead Sponsor:
Medpharmgene, Inc.
Conditions:
Microalbuminuria
Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
Multicenter stepped wedge cluster randomized trial of family practice clinics in Quebec and Ontario comparing the effect of introducing a Point of Care testing (POCT) for urine albumin to usual practi...
Eligibility Criteria
Inclusion
- Male or female 18 years and older and able to visit the study sites every 3 months
- T2D patients with ongoing anti-diabetic therapy for at least 5 years
- Uncontrolled hypertension according to 2012 CHEP recommendations for management of hypertension in diabetic patients ( i.e. BP\> 130/80 mmHg)
- Able and agreeing to provide informed consent.
Exclusion
- Type 1 diabetes patients
- Ongoing therapy with perindopril,
- Known hypersensitivity or allergies to ACEI or sulfonamide derivatives,
- A history of angioedema related or not to previous treatment with ACEI,
- Impaired renal function defined as serum creatinine levels \> 177 µmol/L, eGFR \<30 mL/min,
- Hyperkalemia or hypokalemia,
- Severe hepatic impairment,
- Use of non-antiarrhythmic agents causing torsade de pointes,
- Pregnant or lactating women, or who are planning to become pregnant,
- Any conditions which may impact on participation according to treating physician.
Key Trial Info
Start Date :
April 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2014
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT01907958
Start Date
April 1 2013
End Date
June 1 2014
Last Update
July 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medpharmgene
Montreal, Quebec, Canada, H1Y 3L1